<DOC>
	<DOCNO>NCT00199446</DOCNO>
	<brief_summary>The primary purpose study evaluate efficacy , safety , tolerability 40 mg per day istradefylline ( KW6002 ) patient Restless Legs Syndrome .</brief_summary>
	<brief_title>Study Istradefylline ( KW-6002 ) Treatment Restless Legs Syndrome</brief_title>
	<detailed_description>Restless Legs Syndrome ( RLS ) common neurological disorder prevalence approximately 10 % adult population . It characterize almost irresistible urge move leg , usually accompany feeling intense discomfort . The feeling usually present rest temporarily relieve activity . Symptoms bad even night lead profound sleep disturbance daytime fatigue . Although number therapeutic approach use treat symptom RLS , none universally adopt . While show dopaminergic anti-parkinsonian medication effective treat RLS , use may somewhat limited side effect associate long-term dopaminergic activation . Istradefylline may provide nondopaminergic approach treatment RLS . This study compare efficacy 40 mg per day istradefylline improve symptom RLS placebo .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Istradefylline</mesh_term>
	<criteria>RLS mild moderate severity , nonnursing nonpregnant female , otherwise normal examination . Unable stop RLS medication , treatment exclude medication , abnormal medical status .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Sleep -Sleep Disorder</keyword>
	<keyword>Sleep- Restless Legs Syndrome</keyword>
	<keyword>Clinical Trial</keyword>
</DOC>